Sentences with phrase «future cell therapy»
Finally, the strategy described here may be a valuable tool for creating safer patient - specific cells and thus could have major implications for future cell therapy.
http://journals.plos.org/ Not exact matches
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
Overcoming the immense logistical challenges involved with withdrawing, shipping, modifying, returning, then reinfusing cells for every patient treated paints a scary question mark on the future of cell - based cancer therapies.
We are identifying and supporting work on the technologies of the future: in advanced manufacturing; renewable energy; cell therapy; interconnected digital; intelligent transport; and next generation computing.
By combining this strategy with cancer cell - targeting materials, we should be able to develop a therapy for glioblastoma and other challenging cancers in the future.»
It also provides novel insight into human mesenchymal stem cell - heart cell interactions that can guide future experimental studies to understand the mechanisms underlying mesenchymal stem cell therapy for the heart.
«While expanding beta cell mass may still be desirable for future diabetes therapy, improving the local environment of the otherwise healthy aged beta cell could prevent age - associated deterioration in glucose homeostasis and thereby promote healthy ageing, which is conceptually novel and highly exciting,» says Per - Olof Berggren.
Eventually, it may open the door «to provide therapy in the future to reduce the risk» and protect vulnerable cells.
«By understanding how stress accelerates invasion in aggressive breast tumor cells, this work will inform future studies into whether beta - blockers could be a useful adjuvant therapy in the treatment of some aggressive breast cancers.»
In the right SEM image, T cells (in blue) bind to a section of a completed antigen - presenting cell - mimetic scaffold (in brown), where they are instructed to multiply and are kept alive for future use in T cell therapies.
The number of extracted tumor cells allows conclusions to be drawn with respect to the success of therapy and the future course of the disease.
«I'm not sure if we will ever cure Duchenne muscular dystrophy, but I'm very hopeful that someday in the future, we will have new therapies that correct the ability of muscle stem cells to repair the muscles of afflicted patients and turn this devastating, lethal disease into a chronic but manageable condition.»
«It's not yet clear whether or how GSK3 might be a target for future therapies for B cell - related diseases, but this research opens a lot of doors for further studies,» Rickert said.
«For the broad application of stem cell - derived pituitary cells in the future, cell replacement therapy may need to be customized to the specific needs of a given patient population,» Zimmer says.
His laboratory harnesses the tools of synthetic and chemical biology to engineer the immune cell therapies for cancer and autoimmunity of the future.
In the future, epigenetic editing could also be used to design novel therapies by initiating permanent changes to cell biology.
Ploegh envisions the technique being used to create a new type of personalized therapy in the future — your own cells could be isolated, used to create stem cells that differentiate into erythroblasts, genetically modified to carry a molecule, and reinjected into your body.
Takahashi predicts that in the future, selecting from different stem cell therapies will «depend on the target disease and the situation of the host.»
He hopes that Cas9 - based therapies for T cell - related disorders, which include autoimmune diseases as well as immunodeficiencies such as «bubble boy disease,» will enter the clinic in the future.
Researchers at Norris Cotton Cancer Center have found an antibody that may be used in future treatments for recurrent small - cell lung cancer, which currently has no effective therapy.
Technology such as this, scientists said, may have a promising future in the identification and surgical removal of malignant tumors, as well as using near - infrared light therapies that can kill remaining cancer cells, both by mild heating of them and generating reactive oxygen species that can also kill them.
Stem cells are primitive cells which have the potential to divide endlessly, and the ability to differentiate into any cell type in the body — offering hope for future therapies.
«The successful retrieval of memories in AD mice by increasing the number of spines for normal memory processing only in the memory cells, rather than in a broad population of cells, highlights the importance of highly - targeted manipulation of neurons and their circuits for future therapies.
Together, the knowledge gained in this project will generate new insight into the pathology of the disease as well as help design future therapies for preventing progressive loss of retinal nerve cells and degradation of vision in glaucoma.
Furthermore, this study also encourages the application of iPSC - MSCs as an exciting new therapeutic option for a range of immunological disorders and suggests that further study of the secreted factors may allow the construction of efficient cell - free therapies in the near future.
After hearing a brief explanation that laid out the different sources of stem cells (but left undiscussed their current uses or future potential for therapy), the respondents offered a slightly more nuanced set of views, and only a slight majority (52 %) supported embryonic stem cell research.
The Session Objectives are to detail the progress and future aspirations for translating stem cell therapies to the clinic.
While stem cell therapies hold promise for the treatment of a variety of serious diseases, for most conditions, these treatments are still years in the future.
Not so long ago, human embryonic stem cell (hESC) research and SCNT were being hailed as the future of regenerative medicine, capable of generating cures and therapies for any number of diseases and conditions.
In looking to the future, Shah feels that off - the - shelf CAR T - cell therapies will be key to treating more patients, along with improving durability and response, and improving the current toxicity profile.
Therapeutic strategies aiming at restoring the function of the implicated genes (gene and cell therapies) are very encouraging but not applicable in a near future to the variety of MDs.
«The successful retrieval of memories in AD mice by increasing the number of spines for normal memory processing only in the memory cells, rather than in a broad population of cells, highlights the importance of highly - targeted manipulation of neurons and their circuits for future therapies,» said Tonegawa in a statement.
Future therapies will have to be based on strategies that act by reducing or increasing the number or activity of specific subtypes of pre - and postsynaptic receptors, transporters, and ion channels, or other membrane molecules at the synapse, and by strategies that exploit the new possibilities offered by stem cell technology and targeted repair.
Between partnerships with Pharma, grants from the California Institute for Regenerative Medicine, and other sources of cash, Lewis says that Novocell is «well positioned to ensure we are able support our cell therapy program for the foreseeable future,» and predicts that an ESC product will enter clinical trials in 2012, «if not before then.»
Researchers have identified a novel mechanism by which cells die in Alzheimer's disease, which my aid future therapies targeting cell loss in the brain.
Embryonic cell lines and autologous embryonic stem cells generated through therapeutic cloning have also been proposed as promising candidates for future therapies.
These adult stem cells can be safely and easily collected and can even be stored for possible future use should the individual require stem cell therapy (transplant) later in life.
While the exact contribution adult - born neurons make to overall learning and memory remains mysterious, Song notes that these results are promising for any future nerve stem cell therapy.
However, they remain supportive of basic CRISPR research on animals and non-embryonic human cells to see if human germline gene therapy might be helpful in the future to fix genetic mutations.
The only plausible methods of repairing stochastic nuclear DNA damage look to be the aforementioned advanced molecular nanotechnology, something that lies some decades in the future, or major advances in gene therapy, to the point at which it could be cost - effective and safe to scan and conditionally alter the majority of genes in the majority of cells all at once.
The ASTEP course includes an inclusive array of primary care, specialty and subspecialty topics that were chosen through an assessment of current and future therapeutic applications of stem cell therapies.
Ultimately, we use all this information to establish innovative culture techniques for generating unlimited neural stem cell sources for the derivation of specific types of clinically relevant neuronal or glial cells, for their use in disease modelling and drug discovery platforms, and towards refining their efficacy for future cell replacement - based therapy.
«Completing the Human Cell Atlas is a mammoth task that needs the participation of many international collaborations and the combined knowledge - base will be an immeasurably valuable tool to model the plethora of dynamic components that enable life and to create a resource that can be used to explore new ideas for therapies and diagnostics in the near future».
Tumor heterogeneity, i.e., the differences between cells within one tumor, among different tumor lesions of the same patient, or between patients even if the tumors are of similar genetic signatures, provides major challenges for future therapy.
World Stem Cell Summit and Phacilitate Cell & Gene Therapy World is the only event to showcase the global cord blood and perinatal stem cell field while at the same time placing it in its broader strategic context as a critically important component of future cell, gene and immunotherapy business and production modCell Summit and Phacilitate Cell & Gene Therapy World is the only event to showcase the global cord blood and perinatal stem cell field while at the same time placing it in its broader strategic context as a critically important component of future cell, gene and immunotherapy business and production modCell & Gene Therapy World is the only event to showcase the global cord blood and perinatal stem cell field while at the same time placing it in its broader strategic context as a critically important component of future cell, gene and immunotherapy business and production modcell field while at the same time placing it in its broader strategic context as a critically important component of future cell, gene and immunotherapy business and production modcell, gene and immunotherapy business and production models.
It is conceivable the techniques being developed might have some application in future stem cell therapies in humans where a cloning process was used to generate particular tissues for transplantation.
«The development of a functional human kidney glomerulus chip opens up an entirely new experimental path to investigate kidney biology, carry out highly personalized modeling of kidney diseases and drug toxicities, and the stem cell - derived kidney podocytes we developed could even offer a new injectable cell therapy approach for regenerative medicine in patients with life - threatening glomerulopathies in the future,» said Ingber.
hopefully, future recipients can receive theirs here in the u.s. other states should follow texas» lead, making adult stem cell therapy accessible and affordable to those who, in consultation with a qualified physician.
Once the future stem cell therapist does the therapy, stem cells have the innate potential to produce more cells.»
Understanding how heart muscle cells, or cardiomyocytes, change in space improves efforts for studying disease, screening drugs and conducting cell replacement therapy for future space missions.